Psychiatric illness and regression in individuals with Phelan-McDermid syndrome

被引:60
|
作者
Kohlenberg, Teresa M. [1 ]
Trelles, M. Pilar [2 ,3 ]
McLarney, Brittany [4 ]
Betancur, Catalina [5 ]
Thurm, Audrey [6 ]
Kolevzon, Alexander [2 ,3 ]
机构
[1] Univ Massachusetts, Sch Med, Dept Psychiat, Worcester, MA 01655 USA
[2] Icahn Sch Med Mt Sinai, Seaver Autism Ctr Res & Treatment, New York, NY 10029 USA
[3] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA
[4] Phelan McDermid Syndrome Fdn, Osprey, FL USA
[5] Sorbonne Univ, Inst Biol Paris Seine, Neurosci Paris Seine, CNRS,INSERM, Paris, France
[6] NIMH, Neurodev & Behav Phenotyping Serv, Intramural Res Program, NIH, Bethesda, MD 20892 USA
关键词
Phelan-McDermid syndrome; SHANK3; Mania; Depression; Bipolar disorder; Psychosis; Catatonia; Regression; SCAFFOLDING PROTEIN SHANK3; DELETION SYNDROME; DOWN-SYNDROME; CATATONIA; DISORDERS; SPECTRUM; ONSET; HAPLOINSUFFICIENCY; MUTATIONS; DEMENTIA;
D O I
10.1186/s11689-020-9309-6
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Phelan-McDermid syndrome (PMS) is a genetic condition characterized by intellectual disability, speech and language deficits, hypotonia, autism spectrum disorder, and epilepsy. PMS is caused by 22q13.33 deletions or mutations affecting SHANK3, which codes for a critical scaffolding protein in excitatory synapses. SHANK3 variants are also known to be associated with an increased risk for regression, as well as for psychiatric disorders, including bipolar disorder and catatonia. This study aimed to further describe these phenomena in PMS and to explore any relationship between psychiatric illness and regression after early childhood. Methods Thirty-eight people with PMS were recruited to this study through the Phelan-McDermid Syndrome Foundation based on caregiver report of distinct development of psychiatric symptoms. Caregivers completed a clinician-administered semi-structured interview focused on eliciting psychiatric symptomatology. Data from the PMS International Registry were used to confirm genetic diagnoses of participants and to provide a larger sample for comparison. Results The mean age of the 38 participants was 24.7 years (range = 13 to 50; SD = 10.06). Females (31 of 38 cases; 82%) and sequence variants (15 of 38 cases; 39%) were over-represented in this sample, compared to base rates in the PMS International Registry. Onset of psychiatric symptoms occurred at a mean age of 15.4 years (range = 7 to 32), with presentations marked by prominent disturbances of mood. Enduring substantial loss of functional skills after onset of psychiatric changes was seen in 25 cases (66%). Symptomst indicative of catatonia occurred in 20 cases (53%). Triggers included infections, changes in hormonal status, and stressful life events. Conclusions This study confirms that individuals with PMS are at risk of developing severe neuropsychiatric illness in adolescence or early adulthood, including bipolar disorder, catatonia, and lasting regression of skills. These findings should increase the awareness of these phenotypes and lead to earlier diagnosis and the implementation of appropriate interventions. Our findings also highlight the importance of genetic testing in the work-up of individuals with intellectual disability and acute psychiatric illness or regression. Future research is needed to clarify the prevalence and nature of psychiatric disorders and regression among larger unbiased samples of individuals with PMS.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Consensus recommendations on Epilepsy in Phelan-McDermid syndrome
    de Coo, Irenaeus F. M.
    Jesse, Sarah
    Le, Thuy-Linh
    Sala, Carlo
    EUROPEAN JOURNAL OF MEDICAL GENETICS, 2023, 66 (06)
  • [22] Phelan-mcdermid syndrome and atypical bipolar disorder
    Verhoeven, W.
    Egger, J.
    De Leeuw, N.
    EUROPEAN PSYCHIATRY, 2013, 28
  • [23] Characterisation of the clinical phenotype in Phelan-McDermid syndrome
    Mónica Burdeus-Olavarrieta
    Antonia San José-Cáceres
    Alicia García-Alcón
    Javier González-Peñas
    Patricia Hernández-Jusdado
    Mara Parellada-Redondo
    Journal of Neurodevelopmental Disorders, 2021, 13
  • [24] Opportunities for ABA intervention in Phelan-McDermid syndrome
    Schroeder, Kate A.
    Witts, Benjamin N.
    Traub, Michele R.
    INTERNATIONAL JOURNAL OF DEVELOPMENTAL DISABILITIES, 2022, 68 (06) : 984 - 989
  • [25] Sleep disturbances in Phelan-McDermid syndrome: Clinical and metabolic profiling of 56 individuals
    Moffitt, Bridgette A. A.
    Oberman, Lindsay M. M.
    Beamer, Laura
    Srikanth, Sujata
    Jain, Lavanya
    Cascio, Lauren
    Jones, Kelly
    Pauly, Rini
    May, Melanie
    Skinner, Cindy
    Buchanan, Caroline
    DuPont, Barbara R. R.
    Kaufmann, Walter E. E.
    Valentine, Kathleen
    Ward, Linda D. D.
    Ivankovic, Diana
    Rogers, R. Curtis
    Phelan, Katy
    Sarasua, Sara M. M.
    Boccuto, Luigi
    CLINICAL GENETICS, 2023, 104 (02) : 198 - 209
  • [26] Gait Abnormalities in Children with Phelan-McDermid Syndrome
    Frank, Yitzchak
    Levy, Tess
    Lozano, Reymundo
    Friedman, Kate
    Underwood, Slayton
    Kostic, Ana
    Walker, Hannah
    Kolevzon, Alexander
    JOURNAL OF CHILD NEUROLOGY, 2023, 38 (13-14) : 665 - 671
  • [27] Characterisation of the clinical phenotype in Phelan-McDermid syndrome
    Burdeus-Olavarrieta, Monica
    San Jose-Caceres, Antonia
    Garcia-Alcon, Alicia
    Gonzalez-Penas, Javier
    Hernandez-Jusdado, Patricia
    Parellada-Redondo, Mara
    JOURNAL OF NEURODEVELOPMENTAL DISORDERS, 2021, 13 (01)
  • [28] Incontinence and psychological symptoms in Phelan-McDermid syndrome
    Hussong, Justine
    Wagner, Catharina
    Curfs, Leopold
    von Gontard, Alexander
    NEUROUROLOGY AND URODYNAMICS, 2020, 39 (01) : 310 - 318
  • [29] Dissecting the Heterogeneity of Autism: Focus on Phelan-McDermid Syndrome
    Lamschtein, C.
    Chaffer, T. J.
    EUROPEAN PSYCHIATRY, 2022, 65 : S608 - S608
  • [30] Consensus recommendations on sleeping problems in Phelan-McDermid syndrome
    Casceres, A. San Jose
    Landlust, A. M.
    Carbin, J. M.
    Loth, E.
    EUROPEAN JOURNAL OF MEDICAL GENETICS, 2023, 66 (06)